Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages
Objective: The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma. Method: The data were analyzed following the recommendations contained in the MADRE program of the GENESIS-SEFH report model. Results: Progression free survival and overall survival r...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2018-09-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/10917.pdf |
id |
doaj-3600078b470047499ef6eb85f564fd2f |
---|---|
record_format |
Article |
spelling |
doaj-3600078b470047499ef6eb85f564fd2f2020-11-25T02:27:08ZengGrupo Aula MédicaFarmacia Hospitalaria1130-63432171-86952018-09-01420520421110.7399/fh.10917Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stagesJuan Carlos del Río-Valencia0Rocío Asensi-Díez1M.ª Dolores Fraga-Fuentes2Ana Clopés-Estela3Lorenzo Villalobos-Torres4Servicio de Farmacia, Hospital Regional Universitario de Málaga, MálagaServicio de Farmacia, Hospital Regional Universitario de Málaga, MálagaServicio de Farmacia, Complejo Hospitalario Mancha Centro, Alcázar de San Juan, Ciudad RealHospital Duran I Reynals, Institut Catalá D´Oncología, Hospitalet, BarcelonaServicio de Farmacia, Hospital Regional Universitario de Málaga, MálagaObjective: The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma. Method: The data were analyzed following the recommendations contained in the MADRE program of the GENESIS-SEFH report model. Results: Progression free survival and overall survival results published in the pivotal clinical trial; Tap, WD. et al. (2016) were improvement of 2.5 months in median progression free survival (primary endpoint) HR = 0.672; IC95% (0.442-1.021) and gain of 11.8 months in median OS (secondary endpoint) HR = 0.463; IC95% (0.301-0.710). A cost-effectiveness analyses was performed considering 2 scenarios; scenario 1: with use of whole vials and scenario 2: use of whole vials and associating non-pharmacological costs (day hospital visits, mucositis, neutropenia and dexrazoxane use). In both cases we considered the cost of drugs and the efficacy data of the pivotal clinical trial. In Scenario 1, we would have an Incremental-Cost-Effectiveness-Ratio of €28,443.81/month of progression-free survival and €72,560.74 per year of life gained and in scenario 2 we would have an incremental-cost-effectivenessratio of €30,879.79/ progression-free survival and €78,774.99/ year of life gained. The budgetary impact of this drug would range from €61,759.592 to €92,639.388 estimated to be 800 to 1,200 patients likely to receive treatment in Spain. Conclusions: Olaratumab is a drug that provides a significant benefit in overall survival but not in progression free survival. To be used in soft tissue sarcoma and to be cost-effective, the acquisition cost of the 500 mg vial should be between €101.91 and €506.54 and that of the 190 mg vial between €39.31 and €195.37. http://www.aulamedica.es/fh/pdf/10917.pdfOlaratumabSoft tissue sarcomaCost-effectiveness |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Carlos del Río-Valencia Rocío Asensi-Díez M.ª Dolores Fraga-Fuentes Ana Clopés-Estela Lorenzo Villalobos-Torres |
spellingShingle |
Juan Carlos del Río-Valencia Rocío Asensi-Díez M.ª Dolores Fraga-Fuentes Ana Clopés-Estela Lorenzo Villalobos-Torres Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages Farmacia Hospitalaria Olaratumab Soft tissue sarcoma Cost-effectiveness |
author_facet |
Juan Carlos del Río-Valencia Rocío Asensi-Díez M.ª Dolores Fraga-Fuentes Ana Clopés-Estela Lorenzo Villalobos-Torres |
author_sort |
Juan Carlos del Río-Valencia |
title |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
title_short |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
title_full |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
title_fullStr |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
title_full_unstemmed |
Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
title_sort |
economic evaluation of the genesis-sefh report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages |
publisher |
Grupo Aula Médica |
series |
Farmacia Hospitalaria |
issn |
1130-6343 2171-8695 |
publishDate |
2018-09-01 |
description |
Objective: The economic evaluation of the drug olaratumab is carried out in the treatment of soft tissue sarcoma.
Method: The data were analyzed following the recommendations contained in the MADRE program of the GENESIS-SEFH report model.
Results: Progression free survival and overall survival results published in the pivotal clinical trial; Tap, WD. et al. (2016) were improvement of 2.5 months in median progression free survival (primary endpoint) HR = 0.672; IC95% (0.442-1.021) and gain of 11.8 months in median OS (secondary endpoint) HR = 0.463; IC95% (0.301-0.710). A cost-effectiveness analyses was performed considering 2 scenarios; scenario 1: with use of whole vials and scenario 2: use of whole vials and associating non-pharmacological costs (day hospital visits, mucositis, neutropenia and dexrazoxane use). In both cases we considered the cost of drugs and the efficacy data of the pivotal clinical trial. In Scenario 1, we would have an Incremental-Cost-Effectiveness-Ratio of €28,443.81/month of progression-free survival and €72,560.74 per year of life gained and in scenario 2 we would have an incremental-cost-effectivenessratio of €30,879.79/ progression-free survival and €78,774.99/ year of life gained. The budgetary impact of this drug would range from €61,759.592 to €92,639.388 estimated to be 800 to 1,200 patients likely to receive treatment in Spain.
Conclusions: Olaratumab is a drug that provides a significant benefit in overall survival but not in progression free survival. To be used in soft tissue sarcoma and to be cost-effective, the acquisition cost of the 500 mg vial should be between €101.91 and €506.54 and that of the 190 mg vial between €39.31 and €195.37.
|
topic |
Olaratumab Soft tissue sarcoma Cost-effectiveness |
url |
http://www.aulamedica.es/fh/pdf/10917.pdf |
work_keys_str_mv |
AT juancarlosdelriovalencia economicevaluationofthegenesissefhreportofolaratumabwithdoxorubicininsofttissuesarcomainadvancedstages AT rocioasensidiez economicevaluationofthegenesissefhreportofolaratumabwithdoxorubicininsofttissuesarcomainadvancedstages AT madoloresfragafuentes economicevaluationofthegenesissefhreportofolaratumabwithdoxorubicininsofttissuesarcomainadvancedstages AT anaclopesestela economicevaluationofthegenesissefhreportofolaratumabwithdoxorubicininsofttissuesarcomainadvancedstages AT lorenzovillalobostorres economicevaluationofthegenesissefhreportofolaratumabwithdoxorubicininsofttissuesarcomainadvancedstages |
_version_ |
1724844085622079488 |